Centene Lost 2M Members but Still Generated $1.5B – But the Underlying Picture Remains Strained

What happened

A May 2026 article highlights that Centene lost 2 million customers — primarily from Medicaid redeterminations — yet still generated $1.5 billion in profit, portraying resilience. However, the DeepValue report reveals that this profit figure masks a $6.7 billion goodwill impairment, an elevated health benefit ratio of 92.7%, and ongoing structural margin pressure from ACA morbidity and potential BBBA cuts. The membership loss reflects a deliberate strategy to shed unprofitable ACA enrollees through mid-30% rate hikes, but the reduced book still carries high acuity. Operating cash flow of $4.7 billion in the first nine months of 2025 supports solvency, but the underlying earnings power is far below pre-crisis levels and normalized margins remain elusive. The headline profit is a tactical win, not a strategic recovery, and the core challenges of pricing adequacy and policy risk persist.

Implication

For investors, the $1.5 billion profit is a partial and misleading datapoint. It reflects cash generation and one-time items, not a sustainable earnings trajectory. The DeepValue analysis shows that until the health benefit ratio in ACA and Medicaid segments stabilizes in the low 90s or better, Centene's return on equity will remain below its cost of capital. The membership loss reduces revenue but also lowers risk, yet the remaining pool's morbidity could keep margins thin. Further, potential S&P downgrade and BBBA-driven Medicaid cuts could pressure leverage and contract economics. The stock at ~$47 still trades at 3.8x EV/EBITDA, pricing in some recovery, but the risk/reward is not compelling until clear evidence of HBR improvement emerges. Wait for Q4 2025 results and 2026 ACA enrollment data to confirm the margin repair thesis before adding exposure.

Thesis delta

The news article suggests a positive narrative of profitability despite membership shrinkage, but the DeepValue report counters that the 'profit' is not a clean recovery. The underlying thesis remains 'Wait' because the impairment, elevated HBR, and policy overhang limit upside. No material shift occurs; the risk-reward profile still favors waiting for a cheaper entry or proof of durable margin improvement.